Key Highlights

  • 7.40% was the advance in Schrodinger, Inc. (NASDAQ:SDGR) on November 18, 2026, with shares traded at USD 27.56, a calculated gain of USD 1.90 from a calculated prior close of USD 25.66.
  • 311.51K shares changed hands after a 0.94% gap lower at the open, and the stock then traded 8.42% above the opening level during the regular session on Wednesday.
  • 19% growth lifted third quarter Revenue to USD 64.5 million, while cash, cash equivalents, restricted cash and marketable securities totaled USD 373 million at September 30, 2026, per the company release.
  • 17% growth in annual contract value to USD 44.7 million accompanied a third quarter net loss of USD 37.7 million, or USD 0.50 per share, versus USD 32.8 million a year earlier.

What Moved Schrodinger, Inc. (NASDAQ:SDGR) in Trading on November 18, 2026 (+USD 1.90, +7.40%)

Schrodinger, Inc. traded at USD 27.56 on Wednesday, November 18, 2026, up 7.40%, a calculated USD 1.90 above a calculated prior close of USD 25.66 on November 17, 2026. The stock opened 0.94% below the prior close, a calculated open near USD 25.42, and then traded 8.42% above that open, so the entire advance was built after the first print. Volume reached 311.51K shares, a calculated traded value of about USD 8.6 million at the traded price. Using roughly 75.0 million combined common and limited common shares outstanding at September 30, 2026, the calculated market Capitalization of Schrodinger, Inc. (NASDAQ:SDGR) is about USD 2.07 billion.

The Rationale: Rebound After an Opening Dip for Schrodinger, Inc. (NASDAQ:SDGR)

No company-specific catalyst was identified in published coverage for the session on November 18, 2026. As general context, a rebound after a lower open can reflect sector rotation toward software and life sciences names, short covering or dip buying. The quarter ended September 30, 2026 produced total revenue of USD 64.5 million, up 19%. Software revenue was USD 38.2 million, up 6%, and drug discovery revenue was USD 24.2 million versus USD 13.0 million a year earlier, driven mainly by a milestone payment from Structure Therapeutics. Chief executive Ramy Farid said the company was very pleased with its third quarter performance.

Valuation, Liquidity and Risks for Schrodinger, Inc. (NASDAQ:SDGR)

The company reported a third quarter net loss of USD 37.7 million, or USD 0.50 per share, against USD 32.8 million, or USD 0.45, a year earlier, and adjusted EBITDA of negative USD 16.8 million. Liquidity of USD 373 million comprised about USD 247 million of cash and equivalents, USD 7 million of restricted cash and USD 119 million of marketable securities. Guidance for annual contract value is USD 222 million to USD 232 million, and drug discovery revenue is guided to USD 75 million to USD 85 million, from USD 65 million to USD 75 million previously. Risks include lumpy milestone revenue and continuing net losses.

Where Things Stand

Schrodinger, Inc. (NASDAQ:SDGR) traded at USD 27.56 on November 18, 2026, up 7.40% on volume of 311.51K shares, after opening 0.94% below the prior close. The move came without an identified company-specific catalyst. The company's most recent filing period, the quarter ended September 30, 2026, showed revenue of USD 64.5 million, a net loss of USD 37.7 million and liquidity of USD 373 million. Drug discovery revenue guidance of USD 75 million to USD 85 million for 2026 and annual contract value guidance of USD 222 million to USD 232 million frame the outlook. This article is informational only and is not Investment advice.